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Summary Urokinase plasminogen activator (uPA) is a serine proteinase that has been suggested to play an important role in cancer invasion
and metastasis. It binds to a specific membrane receptor denominated uPA receptor (uPAR). uPA activates plasminogen to form plasmin,
which participates in tissue degradation and proteolysis. Binding of uPA to its receptor accelerates UPA's own activation from pro-uPA,
enhancing the activity of the uPA/uPAR cascade. Using immunohistochemistry and Northern blot analysis, we analysed the role of uPA and
uPAR in 30 human pancreatic cancers. Immunohistochemical analysis demonstrated moderate to strong immunostaining of both factors in
most pancreatic cancers. Cancer lesions with signs of invasion exhibited the strongest immunohistochemical signals for both factors. In
addition, in desmoplastic areas adjacent to the cancer cells, moderate uPA and uPAR immunoreactivity was detectable. Northern blot
analysis revealed a sixfold and a fourfold increase in uPA and uPAR mRNA levels in pancreatic cancer, respectively, in comparison with
normal controls (P<0.01). Correlation of the Northern blot data with the clinical parameters of the patients indicated that patients with
concomitant overexpression of uPA and uPAR had a shorter post-operative survival (median 9 months; mean ± s.d. 10.2±3.6 months) than
patients in whom only one or none of these factors were overexpressed (median 18 months; mean± s.d. 20.3±8.7 months) (P<0.002). Our
data suggest that uPA and uPAR may serve as prognostic markers in human pancreatic cancer and that the marked overexpression of both
factors may create an environment that enables pancreatic cancer cells to invade surrounding tissues.
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Pancreatic cancer has one of the poorest prognoses of all gastro-
intestinal malignancies, being the fourth or fifth leading cause
of cancer-related deaths in Western industrialized countries
(Bomman et al, 1994). Gudjonsson (1987), in his classical review
of 37 000 patients with pancreatic cancer, demonstrated an overall
survival rate of0.4% and a median survival time of5 months after
the diagnosis was established. Once pancreatic cancer is clinically
evident, it progresses at a rapid rate, and metastasis has usually
occurred at the time ofdiagnosis. Consequently, many patients are
not resectable at presentation, and the overall resection rate is
often less than 30% (Gudjonsson 1987; Bomman et al, 1994). The
mechanisms that regulate this aggressive growth behaviour in
pancreatic cancer are not at all clear. Recently, it has been shown
in pancreatic cancer that the concomitant overexpression of the
epidermal growth factor (EGF) receptor and its ligands EGF-,
TGF-alpha (Korc et al, 1992; Yamanaka et al, 1993a) and/or
amphiregulin (Ebert et al, 1994a; Yokoyama et al., 1995a) is asso-
ciated with shorter post-operative survival following tumour
resection. In addition, enhanced expression of c-erbB-3 (Friess et
al, 1995),TGF-fs (Friess et al, 1993a) and basic fibroblast growth
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factor (bFGF) (Yamanaka et al, 1993b), but not of c-erbB-2
(Yamanaka et al, 1993c) or acidic fibroblast growth factor (aFGF)
(Yamanaka etal, 1993b), contributes to tumouraggressiveness and
a poorerprognosis ofpatients with pancreatic cancer.
Several studies indicate that, during cancer cell invasion and
metastasis, proteolytic enzymes may participate in the degradation
ofextracellular matrix components (Fidler et al, 1978; Schmitt et al,
1992). In the past, scientists have focused their attention on the
pathways of plasminogen activation. Plasminogen is an inactive
proenzyme which can be converted to plasmin by two types ofplas-
minogen activators - uPA (urokinase plasminogen activator) and
tPA (tissue plasminogen activator) (Dano et al, 1980). It is tPA
rather than uPA that is mainly involved in physiological activation
ofplasmin during intravascular thrombolysis (Collen, 1985). On the
otherhand,uPA appears toplay apivotalrole in pericellularproteol-
ysis during cell migration and tissue remodelling (Blasi et al, 1987).
uPA is initially released from various cells as an enzymatically
inactive proenzyme (pro-uPA) which can be cleaved by serine
proteinases, cysteine proteinases or thermolysin in its enzymati-
cally active high molecular weight form or by thrombin and gran-
ulocyte elastase in enzymatically inactive high molecular weight
uPA (Schmitt et al, 1992). Both uPA and pro-uPA bind with high
affinity to a specific cell-surface receptor (uPA receptor). The uPA
receptor (uPAR) is a cysteine-rich glycoprotein with an approxi-
mate molecular weight of55-60 kDa. Receptor binding of uPA or
pro-uPA strongly accelerates pro-uPA activation and increases the
enzymatic activity of uPA itself (Ellis et al, 1989). uPA converts
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the zymogen plasminogen to plasmin, an enzyme which degrades
fibrin and a number of other components of the extracellular
matrix, such as type IV collagen, fibronectin and laminin (Liotta et
al, 1981; Dano et al, 1985). Plasmin also activates latent collage-
nases to potentiate their lytic activity (Vassalli et al, 1991; Schmitt
et al, 1992). This activation at the cell surface may enable cells to
exercise a focal and directional proteolysis of the extracellular
matrix. Subsequently, plasmin formation facilitates the passage of
migrating cells through tissue barriers (Estreicher et al, 1990).
Recently, elevated levels of uPA have been reported in prostate
(Achbarou et al, 1994), lung (Pedersen et al, 1994), ovarian
(Schmalfeldt et al, 1995), breast (Jankum et al, 1993; Bianchi at al,
1994) and gastrointestinal carcinomas (Kogha et al, 1989; Takai et
al, 1991; Takeuchi et al, 1993). However, only a few studies of
colon (Pyke et al, 1991) and ovarian carcinomas (Schmalfeldt et
al, 1995) and of breast (Del Vecchio et al, 1993; Duggan et al,
1995) adenocarcinomas have investigated the simultaneous
expression of uPA and its receptor, showing that both factors
appear to play a role in the process of tumour invasion and metas-
tasis (Dano et al, 1992). Because of the high metastatic and inva-
sive potential of human pancreatic cancer cells, we have analysed
in the present study the concomitant expression of uPA and its
receptor in human pancreatic adenocarcinomas.
PATIENTS AND METHODS
Normal human pancreatic tissue samples were obtained from 30
previously healthy individuals (14 women, 16 men; median age 41
years, range 17-59 years) through an organ donor programme.
Pancreatic cancer tissues were obtained from 12 female and 18
male patients undergoing surgery for pancreatic cancer at the
University Hospital of Bern (Bern, Switzerland). The median age
of the pancreatic cancer patients was 66.5 years, with a range of
32-79 years. Surgical procedure consisted of either a partial
duodenopancreatectomy (28 patients) or a left resection of the
pancreas (two patients). Seven patients had a tumour stage I,
eight patients had a tumour stage II and 15 patients had a tumour
stage III. Freshly removed pancreatic tissue samples were fixed
in either Bouin solution or paraformaldehyde for 12-24 h and
paraffin-embedded for histological analysis. Tissues destined
for RNA extraction were frozen in liquid nitrogen immediately
upon surgical removal and maintained at -80°C until use (Kobrin
et al, 1993). The study protocol was approved by the Ethics
Committee of the University of Bern, Switzerland, and the
University ofCalifornia, Irvine, CA, USA.
Northern blot analysis
Total RNA was extracted by the guanidine isothiocyanate method,
size-fractionated on denaturing 1.2% agarose/1.8 M formaldehyde
gels and stained with ethidium bromide for verification of RNA
integrity and loading equivalency (Chomczynski et al, 1987; Korc
et al, 1992; Friess et al, 1993a,b; Yamanaka et al, 1993a). The
RNA was electrotransferred onto Nylon membranes (GeneScreen,
DuPont, Boston, USA) and cross-linked by UV irradiation (Korc
et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a). The blots
were then prehybridized, hybridized and washed under conditions
appropriate for cDNA probes, as previously described (Korc et
al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a). Blots
were prehybridized overnight at 42°C in a buffer that contained
50% formamide, 1% sodium dodecyl sulphate (SDS), 0.75 M
sodium chloride, 5 mm EDTA, 5x Denhardt's solution, 100 g ml-'
salmon sperm DNA, 10% Dextran sulphate and 50 mM dihydrogen
sodium orthophosphate (pH 7.4). The hybridization was carried
out at 42°C for 12 h with the 32P-labelled cDNA probe (lx 106
c.p.m. ml-'). Washing was started by rinsing the blots twice (50°C)
in 2x standard saline citrate (SSC). Afterwards, the blots were
washed three times at 55°C in 0.2x SSC and 2% SDS (Korc et al,
1992; Friess et al, 1993b; Yamanaka et al, 1993a). Blots were then
exposed at -80°C to Fuji radiographic film with intensifying
screens, and the intensity ofthe radiographic bands was quantified
by video densitometry (Biorad 620, USA), as previously reported
(Korc et al, 1992; Friess et al, 1993b; Yamanaka et al, 1993a).
Following membrane hybridization with the uPA and uPAR
cDNA, all the membranes were rehybridized with the 7S cDNA
probe to assess equivalent RNA loading (Korc et al, 1992; Friess
et al, 1993b; Yamanaka et al, 1993a).
cDNA probes were used for filter hybridizations. The uPA
cDNA probe consisted of a 1.5-kb Pstl insert cloned from human
SV40-transformed fibroblast (Blasi et al, 1987), and the uPAR
cDNA probe consisted of a 1.11-kb EcoRI/Xbal insert cloned
from the human fibroblast GM637 cell line which was SV40-
transformed (Roldan et al, 1990). Both cDNAs were obtained
from the American Type Culture Collection (ATCC, Rockville,
MD, USA). The 7S cDNA probe consisted of a 0.19-kb BamHI
fragment of the mouse 7S cytoplasmatic cDNA, which cross-
hybridizes with human 7S RNA (Ebert et al, 1994a). cDNA
probes were radiolabelled with [a-32P]dCTP (3000 Ci mmol-';
DuPont, Boston, USA) to a specific activity of 0.5-lx 109
d.p.m. gg-', using random hexanucleotide primers (Boehringer-
Mannheim, Mannheim, Germany) (Korc et al, 1992; Friess et al,
1993b; Yamanaka et al, 1993a).
uPA and uPAR immunohistochemistry
Consecutive 3- to 5-,um paraffin-embedded tissue sections were
subjected to immunostaining using the streptavidin-peroxidase
technique (Kirkegaard & Perry Laboratories, Gaithersburg, MD,
USA). Tissue sections were submerged for 15 min in Tris-buffered
saline (TBS) (10mM Tris-HCl, 0.85% sodium chloride, pH 7.4)
containing 0.1% (v/v) Triton X-100 and then were washed for5 min
inTBS, as previously reported (Friess et al, 1993b; Yamanaka et al,
1993a). Endogenous peroxidase activity was blocked by incubating
the slides in methanol and in methanol-0.6% hydrogen peroxide,
followed by three washings in methanol and TBS containing 0.1%
bovine serum albumin (BSA) (Friess et al, 1993b; Yamanaka et al,
1993a). Following treatment with hyaluronidase (1 mg ml-' in 100
mm sodium acetate, 0.85% sodium chloride), the sections were
incubated for 30 min at 37°C with 10% normal goat serum before
overnight incubation at4°C with thespecific monoclonal antibodies
(anti-uPA [Muk 11, Biopool, Umea, Sweden; anti-uPAR, American
Diagnostica, Greenwich, CT, USA) diluted in 10% normal goat
serum. Bound antibody was detected with a biotinylated goat anti-
mouse IgG secondary antibody and a streptavidin-peroxidase
complex (Kirkegaard and Perry Laboratories, USA). This was
followed by incubation with diaminobenzidine tetrahydrochloride
(0.05%) as the substrate and then counterstaining with Mayer's
haematoxylin.
To ensure specificity ofthe immunostaining reactions, consecu-
tive sections were incubated either in the absence of the primary
antibody or with a non-immunized mouse IgG antibody. In both
cases, no immunostaining was detected.
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Table 1 Clinical characteristics and Northern blot analysis data in 30 patients with pancreatic cancer
Patient uPA uPAR uPA uPAR Sex Age Stage Operation Survival
no. mRNA mRNA immunostaining immunostaining (years) (UICC) (months)
Tumour Stroma Tumour Stroma
1 - - 0 + 0 - Male 71 III Whipple 14
2 - - 0 - 0 - Male 67 Whipple 29
3 - + 3 - 4 - Male 70 11 Left resection 26a
4 + - 4 - 0 - Male 68 Whipple 21a (Median 18 months)
5 + - 3 - 2 - Male 60 III Whipple 17
6 + - 4 - 0 - Female 79 11 Whipple 15 (Mean 20.3± 8.7 months)
7 + - 5 - 0 - Female 47 Whipple 36a
8 + - 4 - 2 - Female 68 II Whipple 18
9 + - 6 + 0 + Female 61 Whipple 7
10 + + 4 + 4 - Male 70 III Whipple 11
11 + + 5 + 4 + Male 75 III Whipple 8
12 + + 4 - 3 - Female 76 11 Whipple 20a
13 + + 5 - 4 - Female 61 III Whipple 16a
14 + ,+ 5 + 5 + Male 65 11 Whipple 9
15 + + 6 + 5 + Male 68 III Whipple 6
16 + + 5 + 5 + Female 63 III Whipple 6
17 + + 4 + 4 - Male 60 III Whipple 11
18 + + 4 + 4 + Male 62 III Whipple 9 (Median 9 months)
19 + + 4 + 1 + Female 32 Whipple 9
20 + + 5 + 5 + Male 63 Left resection 8 (Mean 10.2 3.6 months)
21 + + 4 + 3 - Male 78 III Whipple 11
22 + + 4 - 4 - Male 50 III Whipple 13
23 + + 4 + 4 - Male 51 11 Whipple 14
24 + + 3 + 4 - Female 73 III Whipple 11
25 + + 3 + 4 - Female 65 Whipple 12
26 + + 4 + 5 + Female 67 III Whipple 7
27 + + 4 + 5 + Male 65 III Whipple 4
28 + + 3 + 3 - Male 69 II Whipple 12
29 + + 4 + 3 + Female 67 11 Whipple 8
30 + + 4 + 4 + Male 66 III Whipple 9
aPatient still alive. mRNA analysis: +, mRNA overexpression vs controls; -, mRNA expression similar to normal controls. Immunohistochemistry:
immunostaining for uPA and uPAR in the tumours and stroma is scored as described in the method section. The upper part of the table lists patients whose uPA
or uPAR mRNA was not simultaneously overexpressed in the tumour samples. The lower part of the table lists patients whose uPA and uPAR mRNA were
concomitantly overexpressed. Patients with concomitant overexpression of uPA and uPAR mRNA in the tumours survived for significantly shorter periods
(P<0.01) than patients in whom only one or none of these factors were overexpressed.
Histopathological analysis of the immunohistochemical results
was performed by two independent pathologists blinded to patient
status, followed by resolution of any differences by joint review
and consultation with a third observer.
The immunohistochemical results were semi-quantitatively
analysed as previously reported (Saeki et al, 1992). The number of
positive cancer cells (cell score) was stratified into four groups: 0,
no cancer cells exhibit immunoreactivity; 1, < 33% ofcancer cells
exhibit immunoreactivity; 2, 33-67% of cancer cells exhibit
immunoreactivity; 3, > 67% of cancer cells exhibit immunoreac-
tivity. The intensity of the immunohistochemical signal (intensity
score) was also stratified into four groups: 0, no immunostaining;
1, weak immunostaining; 2, moderate immunostaining; 3, intense
immunostaining. Finally, the sum of the results of the cell score
and the intensity score was calculated.
Statistical analysis
Results were expressed as median and range. For statistical
analysis, the Wilcoxon test, the linear regression analysis and the
Cox regression were used. Significance was defined as P<0.05.
Survival curves were computed by the method of Kaplan-Meier
and analysed by the Wilcoxon test and the log-rank test.
RESULTS
Immunohistochemical analysis
Immunohistochemical staining of uPA and uPAR and semiquanti-
tative analysis were carried out in the same tumour specimens as
those used for Northern blot analysis. In all cancer samples, there
was close agreementbetween the results obtained by Northern blot
analysis and immunohistochemistry (Table 1).
uPA immunostaining
In the normal human pancreatic tissue samples, weak cytoplasmic
uPA immunoreactivity was present (Figure IA). Approximately
20-30% of the small ductules and the same percentage of blood
vessels exhibited faint uPA immunoreactivity in 25 of 30 (83%)
normal pancreatic tissue samples. In the remaining five normal
samples, no uPA immunostaining was detectable in these cell
types. Only a few pancreatic acinar cells exhibited weak cyto-
plasmic uPA immunoreactivity in the normalpancreas (Figure IA).
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Figure 1 uPA (A) and uPAR (B) immunostaining in the normal human pancreas. A few cells of small ductules and a few acinar cells exhibited uPA
immunoreactivity. A similar pattern was observed for uPAR (B). Original magnification x 400
0?A 1 i i _B ] i
Figure 2 uPA (A) and uPAR (B) immunostaining in human pancreatic cancer. Intense immunostaining of uPA (A) and uPAR (B) was present in the pancreatic
cancer cells. Original magnification x 100
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Figure 3 uPA (A) and uPAR (B) immunostaining in an area with invasion in a human pancreatic cancersample. Intense immunoreactivity of uPA (A) and uPAR
(B) was present in the cancer cells and in the part of the stromal tissue adjacent to the invasion focus. Original magnification x 400
A
Normal Cancer (Figure 3A). In 20 ofthe 30 pancreatic cancer tissues, moderate to __~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.....;... intense uPA immunoreactivity was also present in the stromal
24kb I uPA tissue adjacent to the invasive areas of the tumour (Figure 3A and
-Z I l _ | | - |Table 1). Chronicpancreatitis-like lesions adjacent to the cancer
7S Il_l__cell areas showed moderate uPAimmunostaining in the remaining
degenerating acinar and ductal cells, but not in the fibrotic areas.
B
Normal Cancer
1.4 kb I '-
Figure 4 (A) Northem blot analysis of uPA mRNA. uPA mRNA
the normal pancreas (first six lanes) and was markedly overexi
of nine pancreatic cancersamples (last nine lanes). uPA mRNW
single 2.4-kb band. 7S mRNA, migrating as 0.4-kb species, wa
assess equivalent RNA loading. Exposure times were 5 days f(
for 7S. (B) Northern blot analysis of uPAR mRNA. The order of
normal and cancer samples is the same as shown in (A). uPAF
present in the normal pancreas (first six lanes) and was marke(
overexpressed in eight of nine pancreatic cancersamples (last
The cancer sample which did not have enhanced uPAR mRNA
exhibited overexpression of uPA mRNA. uPAR mRNA migratec
1.4-kb band. 7S RNA, migrating as 0.4-kb species, was used tc
equivalent RNA loading. Exposure times were 5 days for uPAR
In contrast to the normal pancreas, 27 of the 30 ca
exhibited moderate to strong uPA immunostaining i
atic cancer cells (Figure 2A and Table 1). uPA imu
was mainly located in the cytoplasm of the pancreati(
uPAR immunostaining
In normal pancreatic tissue samples, faint cytoplasmic uPAR
uPA receptor immunostaining was observed (Figure IB). In approximately 15%
of the small pancreatic ductules and blood vessels, faint uPAR
7S immunostaining was present. Five to ten per cent of the pancreatic
acinar cells exhibited weak uPAR immunostaining in the normal
was present in pancreas.
pressed in eight In the pancreatic cancer samples, moderate to strong uPAR
A migrated as a immunostaining was observed in the cytoplasm of the cancer cells
ir uPA and 12 h (Figure 2B and Figure 3B). Interestingly, some of the pancreatic
Fthe blotted tumours also exhibited moderate to strong uPAR immunoreac-
3 mRNA was tivity in the nuclei of the cancer cells (Table 1, patient numbers 3,
dlly
nine lanes). 12, 15, 25). However, we could not find any association between
i expression nuclear uPAR immunostaining and increase in mRNA expression
d a single or clinical parameters. Twelve of 30 (40%) pancreatic cancer o assess
and 12 h for 7S tissues also showed moderate to strong uPAR immunoreactivity in
the stromal tissue adjacent to the cancer cells (Figure 3B, Table 1).
Stromal uPAR immunoreactivity was mainly prominent in areas
mncer samples with signs of tumour cell invasion. Analysis of the corresponding
n the pancre- slides of uPA immunostaining demonstrated that all patients
munostaining with uPAR immunostaining in the stroma also exhibited immuno-
c cancer cells reactivity for uPA in these areas.
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Figure 5 Survival curves. Kaplan-Meier plots of the post-operative survival
period in patients whose tumours exhibited concomitant overexpression of
uPA and uPAR ( ) vs patients whose tumours exhibited only
overexpression of uPA or uPAR or patients whose tumours did not
overexpress these factors (--- - -). Log-rank analysis (P<0.006) and the
Wilcoxon test (P<0.003) indicated that there was a significant difference in
survival periods between the two groups
Northern blot analysis
In the normal pancreatic tissue samples obtained from previously
healthy organ donors, low levels of uPA (Figure 4A) and uPAR
(Figure 4B) mRNA were present. Both mRNA moieties were only
weakly visible on the original autoradiographs in all normal
samples. In contrast, 27 of 30 (90%) pancreatic cancer samples
showed markedly increased levels of uPA mRNA (Figure 4A),
and 22 of 30 (73.3%) samples showed markedly increased levels
of uPAR mRNA (Figure 4B and Table 1). Densitometric analysis
of the Northern blots of all cancer samples indicated that uPA
and uPAR were sixfold and fourfold increased, respectively,
in the pancreatic cancer samples in comparison with normal
controls (P<0.01).
Concomitant increased levels ofuPA and uPAR mRNA expres-
sion were detected in 21 of the 30 (70%) pancreatic cancer
samples (Table 1, lower part). Only two pancreatic cancer samples
(6.6%) exhibited mRNA levels for both uPA and uPAR which
were similar to those ofthe normal controls. Six pancreatic cancer
samples (20%) showed only overexpression of uPA, and in one
cancer sample (3.3%) only uPAR mRNA overexpression was
detectable.
Linear regression analysis of the Northern blot results revealed
a significant correlation between the increase of uPA mRNA and
its receptor in the cancer samples (r=0.62, P< 0.001).
To evaluate the clinical significance of the mRNA expression
data in the pancreatic cancer samples, the Northern blot results
were correlated with the survival data after tumour resection
(Table 1). Patients whose tumours exhibited concomitant overex-
pression of uPA and uPAR had significantly shorter median post-
operative survival periods (median 9 months; mean + s.d. 10.2±3.6
months) than patients whose tumours exhibited only overexpres-
sion of uPA or uPAR, as well as significantly shorter survival
periods than patients whose tumours did not overexpress these
factors (median 18 months; mean ± s.d. 20.3± 8.7 months).
This difference was statistically significant when analysed by
either the Wilcoxon test (P<0.003) or the log-rank test (P<0.006)
(Figure 5).
Multivariate analysis using the Cox regression - including uPA
and uPAR mRNA expression, gender, age, tumour stage, type of
operation, completeness of tumour resection and vascular infiltra-
tion - revealed that enhanced uPAR mRNA expression is a strong
independent prognostic parameter for survival in these patients.
DISCUSSION
Cancer ofthe pancreas has a very poor prognosis, and the majority
ofpatients die within a short time afterthe diagnosis has been estab-
lished, regardless of the type of primary treatment they receive
(resection, bypass or stenting). The reasons for the aggressive
growth behaviour of pancreatic cancer cells are not well under-
stood. Recent molecular studies have emphasized the importance of
alterations in growth factors and their receptors in the pathogenesis
ofpancreatic cancer (Hull et al, 1990; Friess et al, 1996). Further-
more, the concomitant overexpression of growth factor receptors
and their ligands has been correlated with a worse prognosis
in pancreatic cancer patients (Yamanaka et al, 1993a,b; Yokomana
et al, 1995a).
An important clinical characteristic ofpancreatic cancer is early
metastasis to lymph nodes and distant organs. However, the mech-
anisms that contribute to the ability of pancreatic cancer cells to
invade normal tissue compartments and other organs and to leave
the primary tumour lesion have not been studied in the past.
Proteinases are enzymes which are involved in proteolysis of
the extracellular matrix, a mechanism which is important in tissue
degradation and remodelling. In human malignancies, four
subgroups of proteinases have been characterized which may
contribute to tumour invasiveness and tumour spread: (a) metallo-
proteinases, (b) aspartyl proteinases, (c) cysteine proteinases and
(d) serine proteinases. Recently, we have reported that metallopro-
teinase-2 and -9 are often overexpressed in human pancreatic
cancers (Gress et al, 1995). In addition, enhanced mRNA expres-
sion of tissue inhibitor of metalloproteinases-1 (TIMP-1) and
TIMP-2 is present in many pancreatic cancer samples (Gress et
al, 1995). These findings suggest that, in pancreatic cancer, up-
regulation of specific metalloproteinases might be important in
tumour pathogenesis and might contribute to remodelling of the
extracellular matrix.
In the present study, we have analysed uPA and uPAR in the
pathogenesis of human pancreatic cancers. Northern blot analysis
demonstrated a sixfold and a fourfold increase in uPA mRNA
and uPAR mRNA expression, respectively, in the pancreatic
cancer samples. In 70% of the pancreatic cancer samples, both
factors were concomitantly overexpressed. Immunohistochemical
analysis revealed the simultaneous presence of uPA and uPAR in
most pancreatic cancer cells. In some cancer samples also, the
stroma and degenerating acinar and ductal cells adjacent to the
cancer lesions exhibited uPA and uPAR immunoreactivity. In
particular, areas with invading cancer cells showed intense uPA
and uPAR immunostaining in the tumour and in the adjacent
stroma.
Our findings with regard to uPA and uPAR overexpression are
in agreement with previous studies carried out in other solid
tumours which indicate that both factors are also often concomi-
tantly present at the protein level and that the presence ofuPA and
uPAR may contribute to tumour invasion and tumour spread
and thereby to worse prognosis (Del Vecchio et al, 1993; Duggan
et al, 1995).
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It is not surprising that uPA and uPAR immunoreactivity were
present primarily in the cytoplasm of the cancer cells. The mono-
clonal antibodies against uPA that were used in our experiments
specifically detect both free and receptor-bound uPA. In addition,
the monoclonal uPAR antibody has been shown to recognize
unbound and ligand-saturated receptor on the surface ofhaemato-
poietic cells, as well as soluble uPAR in the cytoplasm of normal
leucocytes and tumour cells. These binding characteristics of the
anti-uPAR antibody may explain why uPAR immunoreactivity
was mainly detected in the cytoplasm of the cancer cells and not
on the cell surface (Chucholowski et al, 1992).
In four cancer samples, uPAR immunoreactivity was present in
the cytoplasm and in the nuclei ofthe cancer cells. In contrast, we
did not observe nuclear uPAR immunoreactivity in any of the
normal tissue samples, nor was it present in the non-cancerous
regions of the cancer samples. Nuclear uPAR immunostaining in
the cancer cells was not associated with higher levels of uPA or
uPAR gene expression. Furthermore, we could not find any associ-
ation between nuclear uPAR immunostaining and clinical or
histopathological characteristics of the patients. It is not obvious
why uPAR is accumulated in the nuclei of the pancreatic cancer
cells, but it might be possible that uPAR influences gene transcrip-
tion, as it has been previously suggested for some growth factors
and also for uPA (He et al, 1991). Similar nuclearuPAR immunos-
taining has also been observed in some breast cancer samples,
however the significance of this observation in breast cancer was
also not obvious (Carriero et al, 1994).
Concomitant uPA and uPAR immunoreactivity was present in
many pancreatic cancercells in ourstudy. The presence ofboth the
ligand and the receptor in the same cancer cells indicates that
pancreatic cancer cells may have the ability to up-regulate plas-
minogen activation by uPA/uPAR production. Binding of uPA to
its receptor enhances the enzymatic activity of uPA, which then
accelerates the activation ofplasminogen toplasmin. In addition to
these mechanisms, uPAR-bound uPA is involved in the activation
ofgrowth factors. Besides hepatocyte growth factor (HGF) activa-
tion, which can be catalysed by uPA directly, activation of trans-
forming growth factor betas (TGF-js) from their pro-forms, basic
fibroblast growth factor (bFGF) mobilization and extracellular
matrix degradation are mediated by plasmin and by uPAR-bound
or free uPA (Fazioli et al, 1994). These multifactorial effects of
uPA/uPAR on growth factors and the increase in proteolysis might
enhance the ability ofpancreatic cancer cells to migrate, to invade
normal tissue and to metastasize. These effects may be increased
by the additional expression of uPA and uPAR in the surrounding
stroma adjacent to the cancer cells.
In conclusion, we have shown that uPA and uPAR are overex-
pressed in human pancreatic cancer and that overexpression of
both factors is associated with shorter post-operative survival after
tumour resection. The presence of high levels of uPA and uPAR
may be a new prognostic marker that would allow us to identify
patients with poorer prognosis who might benefit from more
aggressive surgical and adjuvant treatment (Ossowski et al, 1991).
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